Study
PLCO
(Learn more about this study)
Project ID
2009-0555
Initial CDAS Request Approval
Dec 15, 2009
Title
Serum Creatinine and Prostate Cancer Risk in the PLCO Study
Summary
In a recent analysis within the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study of male Finnish smokers, we observed a strong prospective association between higher serum creatinine and increased risk of prostate cancer (multivariate OR=2.23, 95% CI 1.33-3.75 for highest vs. lowest quartile, p-trend = 0.0008) (CEBP, 2009;18(10)2643-9). Careful examination of potential confounding factors and exclusions of particular subjects in sensitivity analyses did not alter the risks. The association appeared limited to men who did not receive alpha-tocopherol (vitamin E) supplementation during the trial phase of the ATBC Study (highest quartile OR = 3.36, 95% CI =1.74-6.46, p-trend = 0.0003) compared with those randomized to the alpha-tocopherol supplementation group (OR = 1.02, 95% CI 0.47-2.21, p-trend = 0.66), p-interaction = 0.06. We were unable to evaluate confounding or effect modification by serum prostate specific antigen (PSA) or to evaluate the association in non-smokers. In order to re-examine these findings, we propose to measure serum creatinine in 803 prostate cancer cases and 949 frequency-matched controls from a previously established nested case-control study within the Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. In addition to testing for main effects between baseline serum creatinine and prostate cancer risk, we will be able to take advantage of existing serologic data to explore whether the findings are confounded or modified by serum PSA, smoking status, serum vitamin E, or vitamin E supplement use. Finally, we will examine relationships between the above listed factors among the controls. If the findings from ATBC are replicated, exploration of new avenues in prostate cancer etiology research will be warranted.
Aims
Aim 1: Determine prospectively the association between baseline serum creatinine and prostate cancer risk. Aim 2: Examine whether any observed association between serum creatinine and prostate cancer is confounded or modified by serum PSA, smoking status, serum vitamin E, or vitamin E supplement use (including dosage and duration of use). Also test for effect modification by age; height, weight, and BMI; physical activity; blood pressure; intakes of protein, meat, vitamin E, and alcohol; history of benign prostatic hyperplasia, diabetes, or hypertension; family history of prostate cancer; stage of disease; and time from blood drawing to diagnosis. Aim 3: Among controls, determine whether serum creatinine is related to serum PSA, smoking status, serum vitamin E, or vitamin E supplement use.
Collaborators
Demetrius Albanes (NCI, DCEG)
Barry Graubard (NCI, DCEG)
Stephanie Weinstein (NCI, DCEG)
